节点文献

维生素D受体(VDR)通过调节M2巨噬细胞外泌体SMAP-5介导肝星状细胞的静息(英文)

Vitamin D receptor (VDR) mediates the quiescence of activated hepatic stellate cells (aHSCs) by regulating M2 macrophage exosomal smooth muscle cell-associated protein 5(SMAP-5)

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 刘许文泰吴越李彦懿李凯明侯思源丁明谈敬敏祝子婧汤迎琦刘煜明孙千惠王聪张灿

【Author】 Xuwentai LIU;Yue WU;Yanyi LI;Kaiming LI;Siyuan HOU;Ming DING;Jingmin TAN;Zijing ZHU;Yingqi TANG;Yuming LIU;Qianhui SUN;Cong WANG;Can ZHANG;State Key Laboratory of Natural Medicines/Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases/Center of Advanced Pharmaceuticals and Biomaterials,China Pharmaceutical University;

【通讯作者】 王聪;张灿;

【机构】 中国药科大学高端药物制剂与材料研究中心江苏省代谢性疾病药物重点实验室“天然药物活性组分与药效”国家重点实验室

【摘要】 肝纤维化有效治疗方案的制定需要深入了解其发病机制。肝纤维化的特征是活化的肝星状细胞(a HSC)过度产生细胞外基质。尽管已证实M2巨噬细胞能促进HSC活化,但所涉及的分子机制仍不明确。在此,我们提出参与巨噬细胞极化的维生素D受体(VDR)可能通过改变巨噬细胞外泌体的功能来调节巨噬细胞和HSC之间的通信。本研究证实,激动VDR可以抑制M2巨噬细胞对HSC活化的促进作用。源自M2巨噬细胞的外泌体可以促进HSC活化,同时激动VDR改变了M2外泌体中的蛋白质组分并逆转其激活HSC的作用。平滑肌细胞相关蛋白5(SMAP-5)被发现是M2巨噬细胞外泌体促进HSC活化的关键效应蛋白,其作用机制是通过调节HSC的自噬通量。基于这些结果表明,VDR激动剂和巨噬细胞外泌体分泌抑制剂的联合治疗可获得更加优异的抗肝纤维化效果。本研究旨在阐明VDR和巨噬细胞在HSC激活中的关联,其结果有助于对肝纤维化的发病机制理解,并为肝纤维化的治疗提供潜在的靶点。

【Abstract】 An effective therapeutic regimen for hepatic fibrosis requires a deep understanding of the pathogenesis mechanism. Hepatic fibrosis is characterized by activated hepatic stellate cells(a HSCs) with an excessive production of extracellular matrix. Although promoted activation of HSCs by M2 macrophages has been demonstrated, the molecular mechanism involved remains ambiguous. Herein, we propose that the vitamin D receptor(VDR) involved in macrophage polarization may regulate the communication between macrophages and HSCs by changing the functions of exosomes. We confirm that activating the VDR can inhibit the effect of M2 macrophages on HSC activation. The exosomes derived from M2 macrophages can promote HSC activation, while stimulating VDR alters the protein profiles and reverses their roles in M2 macrophage exosomes. Smooth muscle cell-associated protein 5(SMAP-5) was found to be the key effector protein in promoting HSC activation by regulating autophagy flux. Building on these results, we show that a combined treatment of a VDR agonist and a macrophage-targeted exosomal secretion inhibitor achieves an excellent anti-hepatic fibrosis effect. In this study, we aim to elucidate the association between VDR and macrophages in HSC activation. The results contribute to our understanding of the pathogenesis mechanism of hepatic fibrosis, and provide potential therapeutic targets for its treatment.

【基金】 supported by the National Natural Science Foundation of China (Nos. 81930099,81773664,82130102,92159304,81703585,and 81903651);the Natural Science Foundation of Jiangsu Province (Nos. BK20212011 and BK20180565);the Technology Innovation Project of Nucleic Acid Drug from National Center of Technology Innovation for Biopharmaceuticals (No. NCTIB2022HS01014);the “Double First-Class” University Project (No. CPU2022QZ05);the 111 Project from the Ministry of Education of China;the State Administration of Foreign Expert Affairs of China (Nos. 111-2-07 and B17047);the Fundamental Research Funds for the Central Universities of China (No. 2632022ZD11);the Open Project of State Key Laboratory of Natural Medicines (No. SKLNMZZ202017),China
  • 【文献出处】 Journal of Zhejiang University-Science B(Biomedicine & Biotechnology) ,浙江大学学报B辑(生物医学与生物技术)(英文版) , 编辑部邮箱 ,2023年03期
  • 【分类号】R575.2
  • 【下载频次】41
节点文献中: 

本文链接的文献网络图示:

本文的引文网络